Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old
Public ClinicalTrials.gov record NCT03199053. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial With a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients With Type 2 Diabetes Mellitus Who Are Between 10 and Below 18 Years of Age
Study identification
- NCT ID
- NCT03199053
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 256 participants
Conditions and interventions
Conditions
Interventions
- Dapagliflozin Drug
- Saxagliptin Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 10 Years to 18 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 10, 2017
- Primary completion
- Jan 31, 2023
- Completion
- Jan 2, 2024
- Last update posted
- Jun 20, 2024
2017 – 2024
United States locations
- U.S. sites
- 20
- U.S. states
- 9
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Sacramento | California | 95821 | — |
| Research Site | New Haven | Connecticut | 06519 | — |
| Research Site | Hialeah | Florida | 33012 | — |
| Research Site | Hialeah | Florida | 33016 | — |
| Research Site | Hollywood | Florida | 33021 | — |
| Research Site | Miami | Florida | 33144 | — |
| Research Site | Miami | Florida | 33155 | — |
| Research Site | Miami | Florida | 33165 | — |
| Research Site | Miami Springs | Florida | 33166 | — |
| Research Site | Atlanta | Georgia | 30322 | — |
| Research Site | Atlanta | Georgia | 30341 | — |
| Research Site | Idaho Falls | Idaho | 83404 | — |
| Research Site | Neptune City | New Jersey | 07753 | — |
| Research Site | Memphis | Tennessee | 38116 | — |
| Research Site | Memphis | Tennessee | 38119 | — |
| Research Site | Edinburg | Texas | 78539 | — |
| Research Site | Harlingen | Texas | 78550 | — |
| Research Site | McAllen | Texas | 78503 | — |
| Research Site | San Antonio | Texas | 78229 | — |
| Research Site | Charlottesville | Virginia | 22903 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 102 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03199053, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 20, 2024 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03199053 live on ClinicalTrials.gov.